A double blind placebo controlled trial of ascorbic acid was carried out in 41 severely obese subjects. 38 patients completed the 6 week trial. 19 received 3g of ascorbic acid per day, 19 received placebo. The weight loss during the trial was small in both groups but was significantly greater in the ascorbic acid treated group.
Get full access to this article
View all access options for this article.
References
1.
BrayG. A.KralJ. G.BjorntorpP. (1981). Hepatic sodium potassium dependent ATPase in obesity. The New England Journal of Medicine, 304, 1580–1582.
2.
British National Formulary (1984). Number 7, pp. 152, British Medical Association and Pharmaceutical Press, London.
3.
CantleyL. C.JosephsonL.WarnerR.YanagisawaM.LecheneC.GuidottiG. (1977). Vanadate is a potent (Na-K) ATPase inhibitor found in ATP derived from muscle. Journal of Biological Chemistry, 252, 7421–7423.
4.
De LuiseM.BlackburnG. L.FlierJ. S. (1980). Reduced activity of the red cell sodium potassium pump in human obesity. The New England Journal of Medicine, 303, 1017–1022.
5.
NaylorG. J.McHargA. M.EdwardsL. (1982). A double blind placebo controlled trial of ascorbic acid in obesity. IRCS Medical Science, 10, 848.
6.
SimsE. A. H.DanforthE.HortonE. S.BrayG. A.GlennonJ. A.SalansL. B. (1973). Endocrine and metabolic effects of experimental obesity in man. Recent Progress in Hormone Research, 29, 457.
